

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

J.P. PRIEELS et al.

Serial No.: 08/909,879

Filed: August 12, 1997

For: VACCINE COMPOSITION
CONTAINING ADJUVANTS



Group Art Unit: 1648

Examiner: R. Budens

4/3

TERMINAL DISCLAIMER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Petitioner ("assignee") SmithKline Beecham Biologicals, S.A., duly organized under the laws of the Country of Belgium and having its principal place of business at 89, rue de L'Institute, B-1330 Rixensart, Belgium represents that it is the only assignee of the entire right, title and interest in and to the above-identified application, Serial No. 08/909,879, filed August 12, 1997 for VACCINE COMPOSITION CONTAINING ADJUVANTS in the name of J.P. Prieels et al. as indicated by assignment(s) duly recorded in the United States Patent and Trademark Office at Reel 7367, Frame 0093 and is and at all times was the only assignee of application Serial No. 08/356,372, filed February 17, 1995 (now U.S. Patent No. 5,750,110), for VACCINE COMPOSITION CONTAINING ADJUVANTS in the name of J.P. PRIEELS as indicated by assignment(s) duly recorded in the United States Patent and Trademark Office at Reel 7367, Frame 0093. Assignee SmithKline Beecham Biologicals, S.A. further represents

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

01/18/2000 SDUONG 00000085 08909879

02 FC:148

110.00 0P

that to the best of assignee's knowledge and belief, title to the above-identified application and the United States Patent No. 5,750,110 are in assignee, which is submitting this Terminal Disclaimer.

To obviate a double patenting rejection, Applicants hereby disclaim, under the provisions of 37 C.F.R. § 1.321, the terminal part of any patent granted on the above-identified application, Serial No. 08/909,879, which would extend beyond the expiration date of Patent No. 5,750,110 and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to United States Patent No. 5,750,110, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

In making the above disclaimer, Petitioner does not disclaim the terminal part of any patent granted on Appl. No. 08/909,879 that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of Patent No. 5,750,110, in the event that Patent No. 5,750,110: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

In accordance with the fee schedule set forth in 37 C.F.R. § 1.20(d), the required fee of \$110.00 is being filed with this disclaimer.

If a check for the required fee is not filed concurrently herewith or if there are any additional fees due in connection with the filing of this reply, please charge the fees to our Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.


The undersigned is authorized to act on behalf of assignee SmithKline Beecham Biologicals, S.A.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: _____



Eyal H. Barash
Registration No. 43,483

Date: January 14, 2000